ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 784

Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE

Pablo Castaño-Gonzalez1, Mauricio Restrepo-Escobar1,2, Laura Morales-Maya1, Tomás Urrego1, Simon Sandoval-Alvares1, Carlos Horacio Muñoz1,3, Adriana L Vanegas1,3, Daniel Jaramillo1,4, Gloria Vasquez1 and Luis Gonzalez-Naranjo1, 1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, 2Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, 3Hospital Universitario de San Vicente Fundación, Medellín, Colombia, 4Hospital Universitario de San Vicente Fundación, Medellin, Colombia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Infection, prognostic factors and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is to develop a prognostic prediction model of hospital-acquired bacterial infections in patients with SLE.

Methods: A retrospective cohort of patients with SLE, classified according to the ACR criteria of 1987, with an age ≥ 16 years, hospitalized for ≥4 days for reasons other than bacterial infection in a university hospital between 2011 and 2016 was analyzed. Potential predictors were clinical and laboratory variables obtained during the first hours of hospitalization and selected by review of the medical literature. We compared the episodes in which at least one bacterial infection requiring intravenous antibiotics was diagnosed between days 3 and 15 of hospitalization with those who did not present this outcome. The significant variables in the univariate analysis and with absent data ≤ 20% were included in a multivariate logistic regression model and finally the best performance prediction model was chosen with the most reasonable number of predictors.

Results: 579 hospitalizations were included, 12.4% (n = 72) developed the outcome, the most frequent nosocomial bacterial infection was bacteremia (n = 24), followed by urinary tract infections (n = 19) and pneumonia (n = 13). The main isolated bacteria were Escherichia coli (n = 16) and Staphylococcus aureus (n = 15). Table 1 presents the univariate analysis with selected independent variables. The variables incorporated in the final prediction model were: age, first neutrophil count of hospitalization, SLEDAI calculated on admission, use of central catheter in the first 72 hours, mean glucocorticoid dose in last month and use of antimalarial in last 3 months (table 2). By Receiver Operator Characteristic (ROC) analysis, it was demonstrated that the discrimination capacity of our model was acceptable (area under the ROC curve = 0.7475).

Conclusion: Our model predicts the risk of developing hospital-acquired bacterial infections in patients with SLE, using relatively simple clinical and laboratory data. One of the most important findings was that the use of antimalarials was associated with a significant reduction in the probability of nosocomial bacterial infection. External validation is required to corroborate the results and prospective studies are necessary to evaluate their clinical usefulness and impact.

Table 1. Characteristics of patients. Univariate analysis

Variable

Absent data

Total

(n = 579)

Hospital-acquired bacterial infections

(n = 72)

Without Hospital-acquired bacterial infections

(n = 507)

p

Sex (women)

0 (0%)

512 (88.4%)

64 (87.7%)

448 (88.5%)

0.829

Age (years)

0 (0%)

32 (23)

37 (25)

31.5 (22)

0.085

Duration of the disease (months)

12 (2%)

48 (103)

36 (108)

48 (102)

0.270

Charlson Comorbidity Index

5 (0.8%)

2 (2)

2 (2)

2 (2)

0.572

Leukocytes (cells/mm3)

2 (0.3%)

7000 (4300)

7900 (5400)

6800 (4100)

0.089

Lymphocytes (cells/mm3)

2 (0.3%)

1200 (1200)

900 (1100)

1200 (1100)

0.045

Neutrophils (cells/mm3)

2 (0.3%)

4700 (3600)

5700 (5000)

4600 (3500)

0.007

CRP (mg/dl)

96 (16.6%)

1.5 (3.3)

2.45 (4.44)

1.26 (2.99)

< 0.001

ESR (mm/hour)

234 (40%)

54 (63)

60 (61)

54 (64)

0.729

Creatinine (mg/dl)

15 (2.6%)

0.8 (0.96)

0.97 82.5)

0.8 (0.76)

0.073

Proteins in urinalysis (mg/dl)

143 (25%)

37.5 (150)

112.5 (125)

25 (150)

0.107

Albumin (g/dl)

259 (44.7%)

3 (1.2)

2.45 (1.35)

3.1 (1.15)

< 0.001

Complement C3 (mg/dl)

118 (20.4%)

69 (53)

65 (61)

71 (52)

0.113

Complement C4 (mg/dl)

122 (21.1%)

11.7 (13)

10.6 (18)

11.9 (12.7)

0.612

Anti DNA (titles)

155 (26.8%)

1:20 (160)

0 (160)

1:20 (160)

0.374

Antiphospholipid antibodies

0 (0%)

141 (24.4%)

13 (17.8%)

128 (25.3%)

0.163

Active lupus nephritis

0 (0%)

209 (36.1%)

34 (46.6%)

175 (34.6%)

0.046

Neuropsychiatric lupus

0 (0%)

27 (4.7%)

2 (2.7%)

25 (4.9%)

0.404

SLEDAI

0 (0%)

6 (12)

6 (13)

5 (11)

0.112

Bladder catheter

0 (0%)

16 (2.8%)

6 (8.2%)

10 (2%)

0.002

Central catheter

0 (0%)

37 (6.4%)

15 (20.6%)

22 (4.4%)

< 0.001

Alveolar hemorrhage

0 (0%)

10 (1.7%)

3 (4.1%)

7 (1.4%)

0.095

Mean glucocorticoid dose in last month -prednisolone equivalent- (mg)

0 (0%)

10 (15)

10 (20)

8.75 (15)

0.458

Methylprednisolone pulses

0 (0%)

96 (16.6%)

21 (28.8%)

75 (14.8%)

0.003

Cyclophosphamide in last month

0 (0%)

57 (9.8%)

10 (13.7%)

47 (9.3%)

0.237

Mycophenolate in last month

0 (0%)

94 (16.2%)

12 (16.4%)

82 (16.2%)

0.960

Azathioprine in last month

0 (0%)

85 (14.7%)

11 (15.1%)

74 (14.6%)

0.920

Rituximab in last 6 months

0 (0%)

10 (1.7%)

3 (4.1%)

7 (1.4%)

0.095

Antimalarial in last 3 months

0 (0%)

268 (46.3%)

21 (28.8%)

247 (48.8%)

0.001

Dialysis

0 (0%)

64 (11.1%)

12 (16.4%)

52 (10.3%)

0.117

Table 2. Variables included in the final prediction model of hospital-acquired bacterial infections in patients with SLE

Variable

OR

p

IC 95%

Age

1.0272

0.005

1.0083-1.0465

Neutrophils

1.0001

0.001

1.00005-1.00018

SLEDAI

1.0531

0.003

1.0175-1.0901

Central catheter

5.0763

0.000

2.3690-10.8775

Antimalarial

0.4293

0.005

0.2389-0.7717


Disclosure: P. Castaño-Gonzalez, None; M. Restrepo-Escobar, None; L. Morales-Maya, None; T. Urrego, None; S. Sandoval-Alvares, None; C. H. Muñoz, None; A. L. Vanegas, None; D. Jaramillo, None; G. Vasquez, None; L. Gonzalez-Naranjo, None.

To cite this abstract in AMA style:

Castaño-Gonzalez P, Restrepo-Escobar M, Morales-Maya L, Urrego T, Sandoval-Alvares S, Muñoz CH, Vanegas AL, Jaramillo D, Vasquez G, Gonzalez-Naranjo L. Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prediction-of-hospital-acquired-bacterial-infections-in-patients-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-hospital-acquired-bacterial-infections-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology